Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
Open Access
- 31 December 2023
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (11) , e2305885
Abstract
Resistance to chemotherapy remains a formidable obstacle in acute myeloid leukemia (AML) therapeutic management, necessitating the exploration of optimal strategies to maximize therapeutic benefits. Venetoclax with 3+7 daunorubicin and cytarabine (DAV regimen) in young adult de novo AML patients is evaluated. 90% of treated patients achieved complete remission, underscoring the potential of this regimen as a compelling therapeutic intervention. To elucidate underlying mechanisms governing response to DAV in AML, quantitative phosphoproteomics to discern distinct molecular signatures characterizing a subset of DAV‐sensitive patients is used. Cluster analysis reveals an enrichment of phosphoproteins implicated in chromatin organization and RNA processing within DAV‐susceptible and DA‐resistant AML patients. Furthermore, kinase activity profiling identifies AURKB as a candidate indicator of DAV regimen efficacy in DA‐resistant AML due to AURKB activation. Intriguingly, AML cells overexpressing AURKB exhibit attenuated MCL‐1 expression, rendering them receptive to DAV treatment and maintaining them resistant to DA treatment. Moreover, the dataset delineates a shared kinase, AKT1, associated with DAV response. Notably, AKT1 inhibition augments the antileukemic efficacy of DAV treatment in AML. Overall, this phosphoproteomic study identifies the role of AURKB as a predictive biomarker for DA, but not DAV, resistance and proposes a promising strategy to counteract therapy resistance in AML.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (226‐2022‐00003, 22120230064)
- National Natural Science Foundation of China (82370162, 81820108004, 82170144)
- Key Research and Development Program of Zhejiang Province (2022C03005, 2021C03123)
- Natural Science Foundation of Zhejiang Province (Y23H080018)
This publication has 40 references indexed in Scilit:
- Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) ChromatographyMolecular & Cellular Proteomics, 2016
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- Multiomic Analysis of the UV-Induced DNA Damage ResponseCell Reports, 2016
- An update of current treatments for adult acute myeloid leukemiaBlood, 2016
- A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patientsBlood, 2015
- Development of a Chemical Genetic Approach for Human Aurora B Kinase Identifies Novel Substrates of the Chromosomal Passenger ComplexMolecular & Cellular Proteomics, 2012
- High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemiaLeukemia Research, 2011
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatinNature, 2005
- One‐thousand‐and‐one substrates of protein kinase CK2?The FASEB Journal, 2003